Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK501193PMID: 30000252
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 59-41-6
Drug Levels and Effects
Summary of Use during Lactation
Bretylium is no longer marketed. Because there is little published experience with bretylium during breastfeeding, its high frequency of side effects, and its lack of availability, other agents are preferred.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A dose of 400 mg of bretylium tosylate every 8 hours was taken orally by one mother while nursing a newborn. She was also taking atenolol 25 mg daily, propranolol 20 mg three times a day, spironolactone 75 mg every other day and multivitamin, potassium and magnesium supplements. Jaundice, thought to be unrelated to the drug, occurred at 60 hours of age, but resolved. The infant had appropriate weight gain and development during the first 4 months of life.[1]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Gutgesell M, Overholt E, Boyle R. Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: A case report. Am J Perinatol. 1990;7:144-5. [PubMed: 2331276]
Substance Identification
Substance Name
Bretylium
CAS Registry Number
59-41-6
Drug Class
- Breast Feeding
- Antiarrhythmics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- The distribution of some quaternary ammonium salts in the peripheral nervous system of cats in relation to the adrenergic blocking action of bretylium.[Br J Pharmacol Chemother. 1961]The distribution of some quaternary ammonium salts in the peripheral nervous system of cats in relation to the adrenergic blocking action of bretylium.Boura AL, Duncombe WG, McCoubrey A. Br J Pharmacol Chemother. 1961 Aug; 17(1):92-100.
- Bretylium tosylate versus lidocaine in experimental cardiac arrest.[Am J Emerg Med. 1990]Bretylium tosylate versus lidocaine in experimental cardiac arrest.Vachiery JL, Reuse C, Blecic S, Contempré B, Vincent JL. Am J Emerg Med. 1990 Nov; 8(6):492-5.
- Peripheral vascular effects of bretylium tosylate in man.[Br J Pharmacol Chemother. 1960]Peripheral vascular effects of bretylium tosylate in man.Blair DA, Glover WE, Kidd BS, Roddie IC. Br J Pharmacol Chemother. 1960 Sep; 15(3):466-75.
- Review Sibutramine.[Drugs and Lactation Database (...]Review Sibutramine.. Drugs and Lactation Database (LactMed®). 2006
- Review Bretylium tosylate: profile of the only available class III antiarrhythmic agent.[Clin Ther. 1985]Review Bretylium tosylate: profile of the only available class III antiarrhythmic agent.Anderson JL. Clin Ther. 1985; 7(2):205-24.
- Bretylium - Drugs and Lactation Database (LactMed®)Bretylium - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...